FDA Fast-Tracked Clinical Trial: Accelerating Clinical Trial Enrollment And Enhancing Patient Experience

Slow site activation often creates a critical bottleneck in ophthalmic gene therapy trials, forcing motivated patients to endure exhausting travel for screening visits that frequently end in disqualification. Traditional pre-screening methods rely on basic questionnaires or retrospective medical records rather than protocol-specific clinical assessments, leading to high screen-fail rates and fractured patient experiences. By shifting the clinical evaluation directly to the participant before brick-and-mortar sites are even activated, study teams proactively identify eligible candidates using protocol-aligned imaging and functional assessments at the point of need.

This decentralized strategy completely redefines the enrollment curve, with real-world data showing that over 80% of initial study participants can be pre-screened and qualified before the formal site opening. Explore further how minimizing travel friction keeps candidate pools engaged and provides clinical operations leaders with a scalable blueprint to eliminate delays and elevate data fidelity.